Enanta Pharmaceuticals
ENTA
151 hedge funds and large institutions have $811M invested in Enanta Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 57 increasing their positions, 60 reducing their positions, and 30 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
2.06% more ownership
Funds ownership: 93.87% → 95.93% (+2.1%)
5% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 60
5% less capital invested
Capital invested by funds: $857M → $811M (-$46M)
12% less funds holding
Funds holding: 172 → 151 (-21)
70% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 30
98% less call options, than puts
Call options by funds: $58K | Put options by funds: $3.57M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$36.6M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.23M |
| 3 |
BlackRock
New York
|
+$8.38M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
+$5.06M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$21.8M |
| 2 |
Goldman Sachs
New York
|
-$7.72M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.24M |
| 4 |
First Manhattan
New York
|
-$6.04M |
| 5 |
Man Group
London,
United Kingdom
|
-$2.49M |
ENTA Hedge Fund Activity: Q4 2020 in Review
151 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2020, worth a combined $811M — down 5.4% from $857M a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of ENTA and 9 opened new positions — a net loss of 21 holders — while 60 trimmed existing stakes and 57 added.
The largest buyer was Armistice Capital, adding an estimated $36.6M. The largest seller was Ameriprise, cutting an estimated $21.8M.
- 151 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2020, down from 172 in Q3 2020.
- Funds reported $811M of Enanta Pharmaceuticals stock for Q4 2020, down 5.4% quarter-over-quarter.
- 9 funds opened new Enanta Pharmaceuticals positions in Q4 2020 and 30 closed out, a net change of -21 holders.
- The largest Enanta Pharmaceuticals buyer in Q4 2020 was Armistice Capital, an estimated $36.6M added.
- The largest Enanta Pharmaceuticals seller in Q4 2020 was Ameriprise, an estimated $21.8M sold.
Based on aggregated 13F filings for Q4 2020.